Posts

PIII P3 Health Post Dilution

PIII Trading Playbook – July 29, 2026 PIII (P3 Health Partners) Trading Playbook Date: July 29, 2026 | Current Price: ≈ $11.00 Disclaimer: This is not financial advice. PIII is a low-float micro-cap stock with high volatility. You can lose a significant portion of your capital. Always use proper risk management, position sizing, and do your own research. Past performance is not indicative of future results. Live Charts: • TradingView – PIII Chart • TradingView – Full Chart (new window) Current Setup Snapshot Price: ≈ $11.00 Day Range: $10.57 – $11.50+ 52-Week Range: $1.52 – $16.89 Free Float: ≈ 1.43 million shares (very tight) Short Interest: Low (\~2–3% of float) Analyst Consensus PT: $14.00 Next Catalyst: Q2 2026 Earnings – August 10, 2026 Key Fibonacci Levels Calculated using a practical swing from recent support zone ( $9.50 ) to the 52-week high ( $16.89 ). Difference = $7.39 Fibonacci L...
Post a Comment
Read more

50/50 Playbook Win Rate? Coin toss?!

Why a 50% Win Rate Is Actually a Money Machine in Swing Trading Stop chasing 90% accuracy. The real secret to consistent profitability isn't being right all the time—it's asymmetric upside. If you tell a retail trader or someone outside the market that your trading strategy only wins 50% of the time , they’ll probably tell you to save your time and flip a coin instead. It sounds like bad odds on the surface. But here is the truth that separates seasoned technical traders from amateurs: Win rate is only half of the equation. When you build a system structured around tight invalidation zones and asymmetric upside, hitting a 50% win rate doesn't just keep you afloat—it prints cash. Let's break down the math. The Expectancy Formula Your edge isn't measured by how often you get to brag about a winning play. It's measured by Mathematical Expectancy —the average dolla...
Post a Comment
Read more

WLDS Wearable Devices Going Nowhere?

Sitting on the Sidelines of a Micro-Cap That Keeps Teasing Wearable Devices Ltd. (NASDAQ: WLDS) just printed another one of those sharp, attention-grabbing moves. Up roughly 16% to the $1.55 area on the session, volume higher than the recent quiet days. On the surface it looks like the kind of bounce that makes people lean in and start drawing lines on charts. I’ve been watching it for a while, and the honest reaction is simpler: I don’t know what to feel about it. And that uncertainty is exactly why the rational move right now is to stay on the sidelines. What the company actually is Wearable Devices is an Israeli firm building non-invasive neural input technology. Its wristbands (Mudra Band for the Apple ecosystem, Mudra Link as a more universal option, and the newer Mudra Pro aimed at enterprise and OEMs) let users control phones, computers, AR/VR headsets, and other devices with subtle finger and hand movements. No cameras, no touch required. The pitch sits at the intersect...
Post a Comment
Read more

YAAS Lower Odds

Setup Rating Confidence Score: 38 / 100 View YAAS on TradingView ↗ Rationale: Low score reflects significant structural microcap risks (dilution overhead, wide spreads, rapid decay on failed pops) despite high potential swing returns. ⚠️ Important Disclaimer: This is not financial advice . YAAS (Youxin Technology Ltd) is an extremely high-risk microcap stock with a history of dilution, potential reverse splits, low liquidity, and extreme volatility. You can lose all or a significant portion of your capital. Gaps and share resale registrations can invalidate levels instantly. Probabilities below are rough illustrative estimates based on typical microcap price action, not guarantees. YAAS Potential Swing Trade Scenarios Trade Setup Entry Zone Stop Loss Target 1 Target 2 ...
Post a Comment
Read more

NCPL Not For The NCP

NCPL Update - Wild Swing Trades Wild Swing Trades 📈 NCPL 🎰 Update: Lower Range After Catalyst Window – Still Skillful Gambling Territory July 20, 2026 NCPL (Netcapital Inc.): Lower Range Dynamics, Reduced Short Interest, and What to Watch Next Data as of mid-July 2026. This is an analytical overview for educational and research purposes only. Current Snapshot NCPL has drifted into a lower range since the June 26 analysis. After trading in the $0.55–$0.60 zone, the stock has moved down to the $0.40 – $0.45 area following the July 7 investor call. Volume has dried up significantly (recent sessions often 80k–120k shares). Price: \~$0.42 area Market Cap: ≈ $3.3M – $3.5M Shares Outstanding: ≈ 7.85M Free Float: ≈ 4.4M 52-Week Range: 0.3115 – \~3.63 Recent Volume: Very light TradingView Chart: NASDAQ:NCPL Chart Updated Short-Side Story Short interest has declined meaningfully since the late-May/early-June peaks. A large portion of aggres...
Post a Comment
Read more

UBER — Picking Up?

📊 UBER Key Levels & Risk/Reward Scenarios Analysis Date: July 20, 2026  |  Data as of: ~2:50 PM CDT Current Price $72.40 −$0.07 (−0.09%) • Vol: 11.27M Uber sits in the lower half of its 52-week range after pulling back from the September 2025 high near $102. The setup offers clear levels into the August 5, 2026 earnings catalyst. Key Levels Table Level Type Price % from Current Notes / Confluence Watch For 67.19 Major Support $67.19 −7.2% 52-week low (June 11) + strong June bounce zone High-volume reversal or breakdown 71.59 Near-term Support $71.59 −1.1% Today’s low + recent consolidation floor First line of defense 7...
Post a Comment
Read more

Weekend Summary Report

📊 Equities: Large Cap & Tech Deep Dive $AAPL (Apple Inc.) Confidence Score: 52 / 100 | Strategy: Fibonacci Breakout (LONG) Status Alert: ⚠️ INVALID / OVEREXTENDED (CHASING) Analysis: Script incorrectly logged current entry at $333.74 . The structural setup demands an entry in the $279.19 – $288.06 band. Mark is completely overextended past historical Fibonacci targets ($312.65 / $325.65). Do not engage unless a full structural reset or deep correction occurs. $MSFT (Microsoft Corp.) Confidence Score: 42 / 100 | Strategy: Fibonacci Breakout (LONG) Execution Levels: Entry/Mark: $393.82 | Buy Band: $366.91 – $377.86 | Stop: $366.73 Potential Performance: Target 1 ($408.18): +3.65% | Target 2 ($424.23): +7.72% $NVDA (NVIDIA Corp.) Confidence Score: 50 / 100 | Strategy: Fibonacci Pullback | CORE PLAY COMPLETED Setup Reference: Midpo...
Post a Comment
Read more

LCID

Volume Spike After Relief Rally | Illustrative Risk/Reward Analysis Published: July 17, 2026 Quick Snapshot (as of mid-afternoon July 17): Price: ~ $7.16 – $7.28 area Today’s Move: +10–12%+ on elevated volume (~33M–37M shares vs ~20M avg) Today’s Range: ~6.32 – 7.41 Prev Close: ~6.46 Why LCID Is Moving Today LCID put in a strong momentum day with a clear volume spike after the sharp July 14 scare (intraday drop toward the 52-week low of $2.37 on bankruptcy rumor chatter). The company quickly and firmly denied the rumors, confirming sufficient liquidity well into next year. This relief rally + short-covering pressure created the type of high-volume green day that often catches attention in momentum setups. This fits the classic volume + catalyst near recent support profile many traders watch for. Short interest has remained elevated in recent reports, which can provide additional fuel on continued buying. Key Catalysts &...
Post a Comment
Read more

Lucid — Dreaming?

LCID Momentum Setup – July 17, 2026 LCID (NASDAQ: LCID) Momentum Setup – July 17, 2026 Volume Spike After Relief Rally | Illustrative Risk/Reward Analysis Published: July 17, 2026 Quick Snapshot (as of mid-afternoon July 17): Price: \~ $7.16 – $7.28 area Today’s Move: +10–12%+ on elevated volume (\~33M–37M shares vs \~20M avg) Today’s Range: \~6.32 – 7.41 Prev Close: \~6.46 Why LCID Is Moving Today LCID put in a strong momentum day with a clear volume spike after the sharp July 14 scare (intraday drop toward the 52-week low of $2.37 on bankruptcy rumor chatter). The company quickly and firmly denied the rumors, confirming sufficient liquidity well into next year. This relief rally + short-covering pressure created the type of high-volume green day that often catches attention in momentum setups. This fits the classic volume + catalyst near recent support profile many traders watch for. Short interest has remained elevated in recent reports, which ca...
Post a Comment
Read more

PIII P3 Health -> New Found Wealth?

PIII Technical Analysis: Is Another Momentum Breakout Developing? Date: July 2026 P3 Health Partners (NASDAQ: PIII) has quietly moved back onto the radar after spending several sessions building a consolidation base near the $10 area. Following an overnight move approaching 9%, traders are beginning to ask whether this is simply another short-lived bounce—or the beginning of a larger momentum expansion. Quick Technical Snapshot ✔ Price is attempting to break above recent consolidation. ✔ Previous history shows explosive momentum moves. ✔ Buyers have defended support near $10. ✔ Short-term trend is improving. ✔ Momentum traders may begin watching if volume expands. Overall Technical Outlook: Moderately Bullish Trading Scenario Matrix Potential Entry Initial Target Stretch Target Potential Gain Technical Confidence* Risk $10.40-$10.60 $12.00 $13.75 13%-30% Moderate Medium $10.90-$11.05 $12.75 $15.00 15%-35% ...
Post a Comment
Read more

High-Probability Modest Upside + A Real Shot at Nice Catalyst-Drive Returns

PTGX: High-Probability Modest Upside + Catalyst-Driven Potential If you've been watching Protagonist Therapeutics (NASDAQ: PTGX) , you've probably noticed the stock looking perky. It closed at $135.46 on July 15, 2026 — up $4.19 (+3.19%) — sitting near its 52-week high of $141.10 after a massive run from the lows around $50. This is a classic late-stage biotech story with two major partnered assets nearing potential approval and commercialization in 2026. The setup offers a high probability of a modest near-term return (technical breakout or continued momentum) plus asymmetric upside if the catalysts hit. Company & Pipeline Overview Protagonist Therapeutics is a clinical-stage biotech using its proprietary peptide platform to develop targeted therapies for immunology/inflammation, hematology, and metabolic diseases. Icotrokinra (Icotyde) : First-in-class oral IL-23 receptor antagonist for moderate-to-severe plaque psoriasis. Partnered with Janss...
Post a Comment
Read more